| 000 | 01802 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517170257.0 | ||
| 264 | 0 | _c20171103 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a1699-3993 | ||
| 024 | 7 |
_a10.1358/dot.2017.53.6.2652413 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPaton, D M | |
| 245 | 0 | 0 |
_aNusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. _h[electronic resource] |
| 260 |
_bDrugs of today (Barcelona, Spain : 1998) _cJun 2017 |
||
| 300 |
_a327-337 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAlternative Splicing _xdrug effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCentral Nervous System _xmetabolism |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aExons |
| 650 | 0 | 4 | _aGene Dosage |
| 650 | 0 | 4 | _aHaplorhini |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInjections, Spinal |
| 650 | 0 | 4 |
_aKidney Diseases _xchemically induced |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMulticenter Studies as Topic |
| 650 | 0 | 4 |
_aOligonucleotides _xadministration & dosage |
| 650 | 0 | 4 |
_aOligonucleotides, Antisense _xadministration & dosage |
| 650 | 0 | 4 | _aProtein Stability |
| 650 | 0 | 4 |
_aSpinal Muscular Atrophies of Childhood _xgenetics |
| 650 | 0 | 4 |
_aSurvival of Motor Neuron 1 Protein _xgenetics |
| 650 | 0 | 4 |
_aSurvival of Motor Neuron 2 Protein _xbiosynthesis |
| 650 | 0 | 4 |
_aThionucleotides _xadministration & dosage |
| 650 | 0 | 4 |
_aThrombocytopenia _xchemically induced |
| 650 | 0 | 4 |
_aUp-Regulation _xdrug effects |
| 773 | 0 |
_tDrugs of today (Barcelona, Spain : 1998) _gvol. 53 _gno. 6 _gp. 327-337 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1358/dot.2017.53.6.2652413 _zAvailable from publisher's website |
| 999 |
_c27457131 _d27457131 |
||